Extrastriatal binding of [123I]FP-CIT in the thalamus and pons: gender and age dependencies assessed in a European multicentre database of healthy controls

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 10, 2014, Pages 1938-1946

  Koch, Walter ^a   Unterrainer, Marcus ^a   Xiong, Guoming ^a   Bartenstein, Peter ^a   Diemling, Markus ^b   Varrone, Andrea ^c   Dickson, John C ^d   Tossici Bolt, Livia ^e   Sera, Terez ^f   Asenbaum, Susanne ^g   Booij, Jan ^h   Kapucu, Ozlem L ⁱ   Kluge, Andreas ^j   Ziebell, Morten ^k   Darcourt, Jacques ^l   Nobili, Flavio ^m   Pagani, Marco ^c,n   Hesse, Swen ^o   Vander Borght, Thierry ^p   Van Laere, Koen ^q   Tatsch, Klaus ^r   la Fougère, Christian ^a,s   more..

^a UNIVERSITY OF MUNICH   (Germany)

^b HERMES MEDICAL SOLUTIONS   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^f UNIVERSITY OF SZEGED   (Hungary)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h UNIVERSITY OF AMSTERDAM   (Netherlands)

ⁱ GAZI UNIVERSITY   (Turkey)

^j ABX CRO   (Germany)

^k UNIVERSITY OF COPENHAGEN   (Denmark)

^l CENTRE ANTOINE LACASSAGNE   (France)

^m UNIVERSITY OF GENOA   (Italy)

ⁿ INSTITUTE OF COGNITIVE SCIENCES AND TECHNOLOGIES   (Italy)

^o UNIVERSITY OF LEIPZIG   (Germany)

^p UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^q UNIVERSITY OF LEUVEN   (Belgium)

^r STÄDTISCHES KLINIKUM KARLSRUHE   (Germany)

^s UNIVERSITY OF TÜBINGEN   (Germany)

more..

Author keywords

Age effects; Dopamine transporter; Extrastriatal binding; Gender difference; Serotonin transporter; SPECT; 123I FP CIT

Indexed keywords

2-CARBOMETHOXY-8-(3-FLUOROPROPYL)-3-(4-IODOPHENYL)TROPANE; DOPAMINE TRANSPORTER; PROTEIN BINDING; RADIOPHARMACEUTICAL AGENT; SEROTONIN TRANSPORTER; TROPANE DERIVATIVE;

ADULT; AGE; AGED; ANTIBODY SPECIFICITY; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; NEOSTRIATUM; PONS; SCINTISCANNING; SEX DIFFERENCE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THALAMUS; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOSTRIATUM; ORGAN SPECIFICITY; PONS; PROTEIN BINDING; RADIOPHARMACEUTICALS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEX FACTORS; THALAMUS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 84930687286     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-014-2785-8     Document Type: Article

References (67)

1. Booij J, Speelman JD, Horstink MW, Wolters EC. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med. 2001;28:266–72.
2. Benamer TS, Patterson J, Grosset DG, Booij J, de Bruin K, van Royen E, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord. 2000;15:503–10.
3. Darcourt J, Booij J, Tatsch K, Varrone A, Vander Borght T, Kapucu OL, et al. EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging. 2010;37:443–50. doi:10.1007/s00259-009-1267-x.
4. Walker Z, Cummings JL. [123I]N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iodophenyl)nortropane single-photon emission computed tomography brain imaging in the diagnosis of dementia with Lewy bodies. Alzheimers Dement. 2012;8:74–83. doi:10.1016/j.jalz.2011.08.003.
5. Abi-Dargham A, Gandelman MS, DeErausquin GA, Zea-Ponce Y, Zoghbi SS, Baldwin RM, et al. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT. J Nucl Med. 1996;37:1129–33.
6. Hall H, Halldin C, Guilloteau D, Chalon S, Emond P, Besnard J, et al. Visualization of the dopamine transporter in the human brain postmortem with the new selective ligand [125I]PE2I. Neuroimage. 1999;9:108–16.
7. Madras BK, Gracz LM, Fahey MA, Elmaleh D, Meltzer PC, Liang AY, et al. Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain. Synapse. 1998;29:116–27. doi:10.1002/(SICI)1098-2396(199806)29:2<116::AID-SYN3>3.0.CO;2-A.
8. Varnas K, Halldin C, Hall H. Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. Hum Brain Mapp. 2004;22:246–60. doi:10.1002/hbm.20035.
9. Staley JK, Basile M, Flynn DD, Mash DC. Visualizing dopamine and serotonin transporters in the human brain with the potent cocaine analogue [125I]RTI-55: in vitro binding and autoradiographic characterization. J Neurochem. 1994;62:549–56.
10. Ziebell M, Holm-Hansen S, Thomsen G, Wagner A, Jensen P, Pinborg LH, et al. Serotonin transporters in dopamine transporter imaging: a head-to-head comparison of dopamine transporter SPECT radioligands 123I-FP-CIT and 123I-PE2I. J Nucl Med. 2010;51:1885–91. doi:10.2967/jnumed.110.078337.
11. Booij J, de Jong J, de Bruin K, Knol R, de Win MM, van Eck-Smit BL. Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects. J Nucl Med. 2007;48:359–66.
12. Borgers AJ, Alkemade A, Van de Giessen EM, Drent ML, Booij J, Bisschop PH, et al. Imaging of serotonin transporters with [123I]FP-CIT SPECT in the human hypothalamus. EJNMMI Res. 2013;3:34. doi:10.1186/2191-219X-3-34.
13. Koopman KE, la Fleur SE, Fliers E, Serlie MJ, Booij J. Assessing the optimal time point for the measurement of extrastriatal serotonin transporter binding with 123I-FP-CIT SPECT in healthy, male subjects. J Nucl Med. 2012;53:1087–90. doi:10.2967/jnumed.111.102277.
14. Hesse S, Meyer PM, Strecker K, Barthel H, Wegner F, Oehlwein C, et al. Monoamine transporter availability in Parkinson's disease patients with or without depression. Eur J Nucl Med Mol Imaging. 2009;36:428–35. doi:10.1007/s00259-008-0979-7.
15. Roselli F, Pisciotta NM, Pennelli M, Aniello MS, Gigante A, De Caro MF, et al. Midbrain SERT in degenerative parkinsonisms: a 123I-FP-CIT SPECT study. Mov Disord. 2010;25:1853–9. doi:10.1002/mds.23179.
16. Booij J, Hemelaar TG, Speelman JD, de Bruin K, Janssen AG, van Royen EA. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I]FPCIT SPECT. J Nucl Med. 1999;40:753–61.
17. Rocha FL, Murad MG, Stumpf BP, Hara C, Fuzikawa C. Antidepressants for depression in Parkinson's disease: systematic review and meta-analysis. J Psychopharmacol. 2013;27:417–23. doi:10.1177/0269881113478282.
18. Kugaya A, Sanacora G, Staley JK, Malison RT, Bozkurt A, Khan S, et al. Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors. Biol Psychiatry. 2004;56:497–502. doi:10.1016/j.biopsych.2004.07.001.
19. Lanzenberger R, Kranz GS, Haeusler D, Akimova E, Savli M, Hahn A, et al. Prediction of SSRI treatment response in major depression based on serotonin transporter interplay between median raphe nucleus and projection areas. Neuroimage. 2012;63:874–81. doi:10.1016/j.neuroimage.2012.07.023.
20. Dahlstrom M, Ahonen A, Ebeling H, Torniainen P, Heikkila J, Moilanen I. Elevated hypothalamic/midbrain serotonin (monoamine) transporter availability in depressive drug-naive children and adolescents. Mol Psychiatry. 2000;5:514–22.
21. Heinz A, Ragan P, Jones DW, Hommer D, Williams W, Knable MB, et al. Reduced central serotonin transporters in alcoholism. Am J Psychiatry. 1998;155:1544–9.
22. Hesse S, Barthel H, Murai T, Muller U, Muller D, Seese A, et al. Is correction for age necessary in neuroimaging studies of the central serotonin transporter? Eur J Nucl Med Mol Imaging. 2003;30:427–30. doi:10.1007/s00259-002-1044-6.
23. Kuikka JT, Tammela L, Bergstrom KA, Karhunen L, Uusitupa M, Tiihonen J. Effects of ageing on serotonin transporters in healthy females. Eur J Nucl Med. 2001;28:911–3.
24. Newberg AB, Amsterdam JD, Wintering N, Ploessl K, Swanson RL, Shults J, et al. 123I-ADAM binding to serotonin transporters in patients with major depression and healthy controls: a preliminary study. J Nucl Med. 2005;46:973–7.
25. Pirker W, Asenbaum S, Hauk M, Kandlhofer S, Tauscher J, Willeit M, et al. Imaging serotonin and dopamine transporters with 123I-beta-CIT SPECT: binding kinetics and effects of normal aging. J Nucl Med. 2000;41:36–44.
26. Ryding E, Lindstrom M, Bradvik B, Grabowski M, Bosson P, Traskman-Bendz L, et al. A new model for separation between brain dopamine and serotonin transporters in 123I-beta-CIT SPECT measurements: normal values and sex and age dependence. Eur J Nucl Med Mol Imaging. 2004;31:1114–8. doi:10.1007/s00259-004-1489-x.
27. van Dyck CH, Malison RT, Seibyl JP, Laruelle M, Klumpp H, Zoghbi SS, et al. Age-related decline in central serotonin transporter availability with [(123)I]beta-CIT SPECT. Neurobiol Aging. 2000;21:497–501.
28. Arranz B, Eriksson A, Mellerup E, Plenge P, Marcusson J. Effect of aging in human cortical pre- and postsynaptic serotonin binding sites. Brain Res. 1993;620:163–6.
29. Allen SJ, Benton JS, Goodhardt MJ, Haan EA, Sims NR, Smith CC, et al. Biochemical evidence of selective nerve cell changes in the normal ageing human and rat brain. J Neurochem. 1983;41:256–65.
30. Severson JA, Marcusson JO, Osterburg HH, Finch CE, Winblad B. Elevated density of [3H]imipramine binding in aged human brain. J Neurochem. 1985;45:1382–9.
31. Marcusson JO, Alafuzoff I, Backstrom IT, Ericson E, Gottfries CG, Winblad B. 5-Hydroxytryptamine-sensitive [3H]imipramine binding of protein nature in the human brain. II. Effect of normal aging and dementia disorders. Brain Res. 1987;425:137–45.
32. Andersson A, Sundman I, Marcusson J. Age stability of human brain 5-HT terminals studied with [3H]paroxetine binding. Gerontology. 1992;38:127–32.
33. Derogatis LR, Lipman RS, Covi L. SCL-90: an outpatient psychiatric rating scale – preliminary report. Pychopharmacol Bull. 1973;1:13–28.
34. Beck AT, Steer RA. Beck depression inventory–manual. San Antonio: The Psychological Association; 1987.
35. Varrone A, Dickson JC, Tossici-Bolt L, Sera T, Asenbaum S, Booij J, et al. European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. Eur J Nucl Med Mol Imaging. 2013;40:213–27. doi:10.1007/s00259-012-2276-8.
36. Dickson JC, Tossici-Bolt L, Sera T, de Nijs R, Booij J, Bagnara MC, et al. Proposal for the standardisation of multi-centre trials in nuclear medicine imaging: prerequisites for a European 123I-FP-CIT SPECT database. Eur J Nucl Med Mol Imaging. 2012;39:188–97. doi:10.1007/s00259-011-1884-z.
37. Tossici-Bolt L, Dickson JC, Sera T, de Nijs R, Bagnara MC, Jonsson C, et al. Calibration of gamma camera systems for a multicentre European 123I-FP-CIT SPECT normal database. Eur J Nucl Med Mol Imaging. 2011;38:1529–40. doi:10.1007/s00259-011-1801-5.
38. Chang L. A method for attenuation correction in radionuclide computed tomography. IEEE Trans Nucl Sci. 1978;21:638–43.
39. Willowson K, Bailey D, Schembri G, Baldock C. CT-based quantitative SPECT for the radionuclide 201Tl: experimental validation and a standardized uptake value for brain tumour patients. Cancer Imaging. 2012;12:31–40.
40. Sohlberg A, Watabe H, Iida H. Acceleration of Monte Carlo-based scatter compensation for cardiac SPECT. Phys Med Biol. 2008;53:N277–85. doi:10.1088/0031-9155/53/14/N02.
41. Sohlberg A, Watabe H, Iida H. Optimal collimator design for cardiac SPECT when resolution recovery is applied in statistical reconstruction. J Nucl Med. 2007;48 Suppl 2:721P.
42. Collins DL, Neelin P, Peters TM, Evans AC. Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space. J Comput Assist Tomogr. 1994;18:192–205.
43. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15:273–89. doi:10.1006/nimg.2001.0978.
44. Laruelle M, Slifstein M, Huang Y. Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography. Mol Imaging Biol. 2003;5:363–75.
45. Backstrom I, Bergstrom M, Marcusson J. High affinity [3H]paroxetine binding to serotonin uptake sites in human brain tissue. Brain Res. 1989;486:261–8.
46. De Keyser J, De Backer JP, Ebinger G, Vauquelin G. [3H]GBR 12935 binding to dopamine uptake sites in the human brain. J Neurochem. 1989;53:1400–4.
47. Kupers R, Frokjaer VG, Erritzoe D, Naert A, Budtz-Joergensen E, Nielsen FA, et al. Serotonin transporter binding in the hypothalamus correlates negatively with tonic heat pain ratings in healthy subjects: a [11C]DASB PET study. Neuroimage. 2011;54:1336–43. doi:10.1016/j.neuroimage.2010.09.010.
48. Chou YH, Yang BH, Chung MY, Chen SP, Su TP, Chen CC, et al. Imaging the serotonin transporter using (123)I-ADAM in the human brain. Psychiatry Res. 2009;172:38–43. doi:10.1016/j.pscychresns.2008.12.006.
49. van de Giessen E, Booij J. The SPECT tracer [123I]ADAM binds selectively to serotonin transporters: a double-blind, placebo-controlled study in healthy young men. Eur J Nucl Med Mol Imaging. 2010;37:1507–11. doi:10.1007/s00259-010-1424-2.
50. Koch W, Schaaff N, Popperl G, Mulert C, Juckel G, Reicherzer M, et al. [I-123]ADAM and SPECT in patients with borderline personality disorder and healthy control subjects. J Psychiatry Neurosci. 2007;32:234–40.
51. Du Y, Tsui BM, Frey EC. Model-based compensation for quantitative 123I brain SPECT imaging. Phys Med Biol. 2006;51:1269–82. doi:10.1088/0031-9155/51/5/016.
52. Sun J, Xu J, Cairns NJ, Perlmutter JS, Mach RH. Dopamine D1, D2, D3 receptors, vesicular monoamine transporter type-2 (VMAT2) and dopamine transporter (DAT) densities in aged human brain. PLoS One. 2012;7:e49483. doi:10.1371/journal.pone.0049483.
53. Staley JK, Krishnan-Sarin S, Zoghbi S, Tamagnan G, Fujita M, Seibyl JP, et al. Sex differences in [123I]beta-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers. Synapse. 2001;41:275–84. doi:10.1002/syn.1084.
54. Lavalaye J, Booij J, Reneman L, Habraken JB, van Royen EA. Effect of age and gender on dopamine transporter imaging with [123I]FP-CIT SPET in healthy volunteers. Eur J Nucl Med. 2000;27:867–9.
55. Amir S, Robinson B, Ratovitski T, Rea MA, Stewart J, Simantov R. A role for serotonin in the circadian system revealed by the distribution of serotonin transporter and light-induced Fos immunoreactivity in the suprachiasmatic nucleus and intergeniculate leaflet. Neuroscience. 1998;84:1059–73.
56. Buchert R, Schulze O, Wilke F, Berding G, Thomasius R, Petersen K, et al. Is correction for age necessary in SPECT or PET of the central serotonin transporter in young, healthy adults? J Nucl Med. 2006;47:38–42.
57. Sanchez MG, Morissette M, Di Paolo T. Oestradiol modulation of serotonin reuptake transporter and serotonin metabolism in the brain of monkeys. J Neuroendocrinol. 2013;25:560–9. doi:10.1111/jne.12034.
58. Volkow ND, Fowler JS, Wang GJ, Logan J, Schlyer D, MacGregor R, et al. Decreased dopamine transporters with age in healthy human subjects. Ann Neurol. 1994;36:237–9.
59. De Keyser J, Ebinger G, Vauquelin G. Age-related changes in the human nigrostriatal dopaminergic system. Ann Neurol. 1990;27:157–61.
60. Mozley PD, Acton PD, Barraclough ED, Plossl K, Gur RC, Alavi A, et al. Effects of age on dopamine transporters in healthy humans. J Nucl Med. 1999;40:1812–7.
61. Schwarz J, Storch A, Koch W, Pogarell O, Radau PE, Tatsch K. Loss of dopamine transporter binding in Parkinson's disease follows a single exponential rather than linear decline. J Nucl Med. 2004;45:1694–7.
62. Bannon MJ, Whitty CJ. Age-related and regional differences in dopamine transporter mRNA expression in human midbrain. Neurology. 1997;48:969–77.
63. Booij J, de Win MM. Brain kinetics of the new selective serotonin transporter tracer [123I]ADAM in healthy young adults. Nucl Med Biol. 2006;33:185–91. doi:10.1016/j.nucmedbio.2005.10.005.
64. Lee NJ, Park IS, Koh I, Jung TW, Rhyu IJ. No volume difference of medulla oblongata between young and old Korean people. Brain Res. 2009;1276:77–82. doi:10.1016/j.brainres.2009.04.027.
65. Raz N, Gunning-Dixon F, Head D, Williamson A, Acker JD. Age and sex differences in the cerebellum and the ventral pons: a prospective MR study of healthy adults. AJNR Am J Neuroradiol. 2001;22:1161–7.
66. Shioe K, Ichimiya T, Suhara T, Takano A, Sudo Y, Yasuno F, et al. No association between genotype of the promoter region of serotonin transporter gene and serotonin transporter binding in human brain measured by PET. Synapse. 2003;48:184–8. doi:10.1002/syn.10204.
67. Laruelle M, Vanisberg MA, Maloteaux JM. Regional and subcellular localization in human brain of [3H]paroxetine binding, a marker of serotonin uptake sites. Biol Psychiatry. 1988;24:299–309.